DARE (Dare Bioscience) GF Value : $0.00 (As of Apr. 05, 2025)

View and export this data going back to 2014. Start your Free Trial

What is Dare Bioscience GF Value?

As of today (2025-04-05), Dare Bioscience's share price is $2.895. Dare Bioscience's GF Value is $0.00. Therefore, Dare Bioscience's Price-to-GF-Value for today is . Based on the relationship between the current stock price and the GF Value, GuruFocus believes Dare Bioscience is Not Valued.

The GF Value represents the intrinsic value of a stock, determined using GuruFocus' proprietary methodology. The GF Value Line on our stock Summary page provides an estimate of the stock’s fair-trading value.

To calculate this value, GuruFocus follows these steps:

We analyze historical correlations between the stock price and key business performance metrics, such as revenue, earnings, cash flow, and book value.
We identify the metrics that have the strongest historical correlation with the stock price and determine the historical multiples at which the stock has traded relative to these metrics.
Using these historical multiples as a reference, we estimate the stock's fair value while accounting for future business growth. Adjustments may be made based on the company’s past returns and growth trends.

GuruFocus believes that the GF Value Line represents the fair value at which a stock should trade. Stock prices typically fluctuate around this line. If a stock’s price is significantly above the GF Value Line, it is considered overvalued, and its future returns are likely to be lower. Conversely, if the stock price is significantly below the GF Value Line, its future returns are likely to be higher.

Please note that "Possible Value Trap, Think Twice" applies to companies that appear significantly undervalued but are either experiencing a long-term business decline or facing financial distress.

Dare Bioscience (NAS:DARE) GF Value Explanation

Based on the relationship between the current stock price and the GF Value, GuruFocus provides the following 6 ratings:

Posssible Evaluations	All-in-One Screener Examples (2)
Possible Value Trap, Think Twice (1)	Predictable Companies that possibly be Value Traps
Significantly Overvalued	Predictable Companies which are Significantly Overvalued
Modestly Overvalued	Predictable Companies which are Modestly Overvalued
Fairly Valued	Predictable High Quality Companies which are Fairly Valued
Modestly Undervalued (3)	Predictable High Quality Companies which are Modestly Undervalued
Significantly Undervalued (3)	Predictable High Quality Companies which are Significantly Undervalued

(1) "Possible Value Trap, Think Twice" applies to companies that appear significantly undervalued but are either experiencing a long-term business decline or facing financial distress.

(2) These are some simple examples. You can access our GF Valuation filter under All-in-One Screener’s Fundamental tab, and Price-to-GF-Value filter under Valuation Ratio tab and set your own criteria.

(3) A sufficient margin of safety exists only when the stock is undervalued.

Dare Bioscience's Price-to-GF-Value for today is calculated as

Price-to-GF-Value	=	Share Price	/	GF Value
	=	2.895	/	0.00
	=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Dare Bioscience GF Value Related Terms

Thank you for viewing the detailed overview of Dare Bioscience's GF Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Dare Bioscience Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Dare Bioscience Inc (NAS:DARE) » Definitions » GF Value

Comparable Companies

Traded in Other Exchanges

N/A

Address

3655 Nobel Drive, Suite 260, San Diego, CA, USA, 92122

Website

https://www.darebioscience.com

Dare Bioscience Inc is a biopharmaceutical company committed to advancing innovative products for women's health. The company identifies, develops and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in advanced clinical development namely, Ovaprene and Sildenafil Cream. It has one operating segment, women's health.

Executives

Sophia Nnenna Ononye-onyia	director	1270 AVE OF THE AMERICAS, 7TH FL - 1026, NEW YORK NY 10020
Sabrina Martucci Johnson	director, officer: Chef Executive Officer	11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037
John A Fair	officer: Chief Strategy Officer	C/O DARE BIOSCIENCE, INC., 11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037
Cheryl R Blanchard	director	C/O ZIMMER, INC., P.O. BOX 708, WARSAW IN 46580
Roger Hawley	director	3655 NOBEL DRIVE, SUITE 260, SAN DIEGO CA 92122
Gregory W Matz	director	1 WHITE OAK WAY, NOVATO CA 94949
Jessica D. Grossman	director	C/O DARE BIOSCIENCE, INC., 11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037
Lisa Walters-hoffert	officer: Chief Financial Officer	C/O DARE BIOSCIENCE, INC., 10210 CAMPUS POINT DRIVE, SUITE 150, SAN DIEGO CA 92121
Robin Joan Steele	director	3280 BAYSHORE BOULEVARD, BRISBANE CA 94005
Scott Eliasof	officer: SVP, Chief Scientific Officer	C/O CERULEAN PHARMA INC., 35 GATEHOUSE DRIVE, WALTHAM MA 02451
David R Walt	director	5200 ILLUMINA WAY, SAN DIEGO CA 92122
Adrian Senderowicz	officer: SVP, Chief Medical Officer	C/O PUMA BIOTECHNOLOGY, INC., 10880 WILSHIRE BOULEVARD, SUITE 2150, LOS ANGELES CA 90024
Stuart A Arbuckle	director	VERTEX PHARMACEUTICALS INCORPORATED, 130 WAVERLY ST., CAMBRIDGE MA 02139
Alejandra Carvajal	officer: VP, General Counsel	C/O CERULEAN PHARMA INC., 840 MEMORIAL DRIVE, 5TH FLOOR, CAMBRIDGE MA 02139
James E Oneill	officer: Principal Accounting Officer	15 GREENBRIAR CIRCLE, ANDOVER MA 01810